Clinical Trials Browser

Breast Neoplasms × lenvatinib × 90 days × Clear all

NCT06110793 2026-03-30

A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer

Phase 1/2 Recruiting

Breast Neoplasms